BiassoniE, AssiniA, GandogliaI, et al.The importance of thinking about Guillain-Barré syndrome during the COVID-19 pandemic: A case with pure dysautonomic presentation. J Neurovirol, 2021; 27(4):662–665; doi: 10.1007/s13365-021-00997-7
2.
FinstererJ, ScorzaFA, ScorzaCA, et al.Extrapulmonary onset manifestations of COVID-19. Clinics (Sao Paulo), 2021; 76:e2900; doi: 10.6061/clinics/2021/e2900
3.
GigliGL, VogrigA, NiloA, et al.HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. Neurol Sci, 2020; 41(12):3391–3394; doi: 10.1007/s10072-020-04787-7
4.
KoikeH, KatsunoM. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: Insights into classification and therapeutic strategy. Neurol Ther, 2020; 9(2):213–227; doi: 10.1007/s40120-020-00190-8
5.
MeidaninikjehS, SabouniN, TaheriM, et al.SARS-CoV-2 and Guillain-Barré syndrome: Lessons from viral infections. Viral Immunol, 2022; 35(6):404–417; doi: 10.1089/vim.2021.0187
